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Tokyo and Saitama, JapanABSTRACT
Background: Near-infrared spectroscopy (NIRS) allows continuous noninvasive monitoring of changes in the tissue levels
of oxygenated hemoglobin (O2Hb) and deoxygenated hemoglobin (HHb) and can identify the severity of chronic venous
diseases. Here we investigated the predictors of post-thrombotic syndrome (PTS) using NIRS in patients with a ﬁrst
episode of deep venous thrombosis (DVT).
Methods: The study enrolled 129 patients with DVT. Risk factors in each patient were assessed at presentation. Venous
abnormalities conﬁrmed by ultrasound and parameters derived from NIRS were evaluated at 6 months after DVT. On
standing, increases in O2Hb and HHb (DO2Hbst and DHHbst) and the times taken for each concentration to become
maximal (TO2Hbst, and THHbst) were measured. During 10 tiptoe movements, O2Hb showed a continuous decrease
(DO2Hbex), whereas venous expulsion (DHHbEex) and subsequent retention (DHHbRex) were observed. The oxygenation
index (HbD; HbD ¼ O2Hb  HHb) was also calculated at the end of standing and at the end of 10 tiptoe movements
(DHbDst and DHbDex). Final clinical manifestations were evaluated at 6 years, and PTS was considered to be present if the
Villalta score was $5.
Results: Thirteen patients were excluded and 116 patients were ﬁnally included. Of these, 19 (16%) developed PTS. Among
various NIRS-derived parameters, TO2Hbst had the highest area under the curve (0.88; 95% conﬁdence interval [CI], 0.80-
0.93; P < .01) with the best cutoff value (TO2Hbst#48 seconds). On univariate analysis, variables associated with greater risk
for development of PTS were stroke (odds ratio [OR], 5.59; 95% CI, 0.74-42.41; P ¼ .06), idiopathic DVT (OR, 4.13; 95% CI, 1.36-
12.55; P < .01) and iliofemoral DVT (OR, 4.31; 95% CI, 1.48-12.60; P < .01) at initial presentation, venous occlusion combined
with reﬂux (OR, 4.24; 95% CI, 1.50-12.00; P < .01), and NIRS-derived TO2Hbst #48 seconds (OR, 43.03; 95% CI, 9.04-204.81;
P < .01) at 6 months. Multivariate logistic regression analysis ﬁnally revealed venous occlusion combined with reﬂux (OR,
4.80; 95% CI, 1.03-22.36; P < .05) and NIRS-derived TO2Hbst #48 seconds (OR, 53.73; 95% CI, 8.43-342.41; P < .01) to be
independently associated with PTS progression.
Conclusions: NIRS-derived TO2Hbst #48 seconds is a promising time-course predictor of PTS progression. (J Vasc Surg:
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x.doi.org/10.1016/j.jvsv.2016.05.008It has been reported that post-thrombotic syndrome
(PTS) is present in 20% to 40% of patients with deep
venous thrombosis (DVT) and severe in 5% to 10% of
them.1,2 Recent studies have shown that risk factors for
PTS include ipsilateral recurrent DVT, obesity, mild
contralateral venous insufﬁciency, and residual venous
obstruction demonstrated by baseline ultrasound.3,4
However, severe symptoms of PTS may also develop
over time in patients with no apparent history of recur-
rent DVT. Therefore, reliable identiﬁcation of patients
who are likely to develop PTS in the acute phase of
DVT is difﬁcult.
Near-infrared spectroscopy (NIRS) allows continuous
noninvasive monitoring of changes in tissue levels of
oxygenated hemoglobin (O2Hb) and deoxygenated he-
moglobin (HHb) and can clarify the severity of chronic
venous diseases. Previously, we reported that increased
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associated with clinical deterioration of post-thrombotic
symptoms and found that increased calf muscle deoxy-
genation was an important follow-up variable for pre-
dicting the development of PTS.5 More recently, we
found signiﬁcant differences in NIRS-derived parameters
between patients with and without PTS using quantita-
tive measurements of calf muscle O2Hb and HHb levels
by NIRS.6 Therefore, the primary purpose of this study
was to evaluate predictors of PTS, including characteris-
tics evident at initial presentation and follow-up param-
eters determined by NIRS at a relatively early stage of
DVT, to determine their prognostic impact on PTS
development.METHODS
Patients. Subjects potentially eligible for this study
were 129 consecutive patients with a ﬁrst episode of uni-
lateral acute DVT who received anticoagulation therapy
between April 2006 and March 2009. The baseline risk
factors for venous thromboembolism investigated
included age, gender, body mass index (BMI), presence
of active cancer, congestive heart disease, hormone
replacement therapy, immobilization, renal failure, sur-
gery, and stroke. Idiopathic (unprovoked) DVT was
deﬁned as DVT occurring in the absence of the triggering
factors listed before. Patients with an ankle-brachial
pressure index of <0.9 and those with thrombophilia,
recurrent DVT, ﬁxed joints, muscle atrophy or weakness,
or limb swelling due to systemic diseases or lymphe-
dema were excluded, as were patients with inadequate
follow-up or data acquisition.
Venous duplex ultrasound. The initial diagnosis of
acute DVT was made by venous duplex ultrasound ex-
amination using a color duplex ultrasound scanner
(LOGIQ S8: PRO; GE Healthcare Japan, Tokyo, Japan)
with a 5-10 MHz linear array transducer. Iliofemoral DVT
was diagnosed if the proximal veins were completely
occluded with venous thrombus extending proximally
to the external iliac vein. Femoropopliteal DVT was diag-
nosed if the proximal veins had thrombi without iliac
involvement.
After initial diagnosis, patients with proximal DVT were
administered unfractionated heparin intravenously for 5
to 14 days during the acute phase, adjusted to maintain
the activated partial thromboplastin time at 1.5 to 2.5
times the control value, followed by oral warfarin for at
least 8 weeks at an international normalized ratio level
of 2 to 3. Patients with calf vein thrombosis received oral
warfarin alone. All patients were encouraged to ambulate
and wore graduated thigh-high compression stockings
for at least 6 months immediately after diagnosis.
Development of venous reﬂux at the follow-up visit was
also investigated using duplex ultrasound. Reﬂux times
of >0.5 second for superﬁcial and perforating veins and>1.0 second for deep veins were considered to indicate
incompetence.
NIRS. Changes in calf muscle O2Hb and HHb were
measured by NIRS (OM-200 or OM-300; Shimadzu
Corp, Kyoto, Japan) using a light source emitting four
laser beams of different wavelength (690 nm, 780 nm,
805 nm, and 830 nm), employed in order. According to
the variations in optical density at each wavelength,
O2Hb, HHb, and total hemoglobin are calculated on the
basis of the Lambert-Beer law,7 whereby the change in
the hemoglobin concentration can be calculated from
the variation in optical density relative to the initial value.
As light travels in a shallow arc to a penetration depth of
about half the separation distance into the tissue, the
penetration depth was estimated to be 2 cm because
the light emitter-detector distance of the device we
employed was 4 cm.8 Changes in the hemoglobin con-
centration were expressed as absolute values.
Recently, we developed a new method for identifying
changes in calf muscle O2Hb and HHb in patients with
chronic venous diseases using NIRS.6,9 First, using adhe-
sive tape, the sensor was placed ﬁrmly on the posterior
aspect of the calf, over the medial head of the gastrocne-
mius muscle. Baseline NIRS recording was performed
while the patient remained supine for 5 minutes with
the leg elevated on a foam block in a quiet room at a con-
stant temperature of 22C to 25C. The patient then adop-
ted a standing position without putting any weight on the
studied leg, resulting in increases of both O2Hb and HHb.
The patient was then asked to keep still until plateaus had
been reached, and increases in O2Hb and HHb were
calculated by subtracting the baseline value from the
maximum value (DO2Hbst and DHHbst). The time elapsed
until the maximum increases in the O2Hb and HHb con-
centrations (TO2Hbst, and THHbst) was also measured.
The patient was then asked to perform 10 tiptoe move-
ments with weight bearing on both legs, resulting in a
continuous decrease of O2Hb. The relative change in
O2Hb was calculated by subtracting the value measured
at the end of exercise from that at the beginning of exer-
cise (DO2Hbex). On the other hand, these 10 tiptoe move-
ments also resulted in venous expulsion (DHHbEex) and
subsequent retention (DHHbRex).
10 The oxygenation in-
dex (HbD; HbD ¼ O2Hb  HHb) was also calculated at
the end of standing and 10 tiptoe movements (HbDst
and HbDex; Fig 1).
11 It took approximately 4 to 5 minutes
to complete the examination, and the 10 tiptoe move-
ments were completed within 10 seconds.
Study outcome. The primary end point of this study
was the development of PTS. The follow-up protocol
was an outpatient visit at 2 weeks, 1 month, 3 months, 6
months, and every 6 months thereafter. Ultrasound-
conﬁrmed venous abnormalities and NIRS-derived pa-
rameters were evaluated by an experienced examiner at
Fig 1. Near-infrared spectroscopy (NIRS) examination. A1, Maximum increase in oxygenated hemoglobin (O2Hb)
on standing (DO2Hbst). A2, Time elapsed until the maximum increase in O2Hb (TO2Hbst). A3, Maximum increase
in deoxygenated hemoglobin (HHb) on standing (DHHbst). A4, Time elapsed until the maximum increase in
HHb (THHbst). A5, Oxygenation index at the end of standing (HbDst). B1, Maximum decrease in O2Hb during
exercise (DO2Hbex). B2, Venous expulsion during exercise (DHHbEex). B3, Venous retention during exercise
(DHHbRex). B4, Oxygenation index at the end of exercise (HbDex). dOxy, deoxygenated hemoglobin; Oxy,
Oxygenated hemoglobin; Ttl, total hemoglobin.
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evaluated at 6 years after diagnosis of DVT, and follow-up
of the ﬁnal patient was completed in March 2015. PTS
was considered to be present if the Villalta score was
$5.12 A score of 5 to 9 was categorized as mild disease, 10
to 14 as moderate disease, and $15 or presence of venous
ulcer as severe disease. Moreover, to assess the clinical
severity of PTS, the Clinical, Etiologic, Anatomic, and
Pathophysiologic (CEAP) classiﬁcation of the reporting
standards for venous diseases was employed.13 The study
protocol was approved by the Institutional Review Board,
and all subjects provided informed consent.
Statistical analysis. All data were analyzed using the
IBM SPSS Statistics package (version 22; IBM Corp,
Armonk, NY). Comparisons of numerical data between
patient groups were performed using Student t-test,
and differences between proportions were evaluated
by c2 contingency table analysis or Fisher exact test.
Continuous data were expressed as mean 6 standard
deviation. Statistical signiﬁcance was deﬁned as P <
.05. The patients’ age, gender, BMI, risk factors for venous
thromboembolism, and anatomic distributions of DVT
were assessed at the baseline, and time-course vari-
ables including venous abnormalities and NIRS-derived
parameters were evaluated at 6 months after the onset
of DVT. Receiver operating characteristic curves were
used to evaluate the NIRS-derived parameters. To iden-
tify factors that were independent predictors of PTS,potential confounding variables were ﬁrst chosen using
univariate analysis (P < .10) and then subjected to
multivariate logistic regression analysis.
RESULTS
Patient characteristics. Among the 129 patients evalu-
ated, 13 were excluded from the study because of inade-
quate follow-up or inadequate data acquisition. Thus, 116
patients were ﬁnally included (Fig 2). These comprised 42
men and 74 women with a mean age of 62 years; 13%
were aged <40 years, 35% 40 to 65 years, and 52% >65
years. The patients’ mean BMI was 24 kg m2; in terms of
BMI classiﬁcation, 3% were classiﬁed as underweight
(<18.5 kg m2), 62% as normal (18.5-25 kg m2), 31% as
overweight (25-30 kg m2), and 3% as obese ($30 kg
m2). Thirty-six patients (31%) had unprovoked DVT, and
the remaining 80 (69%) had provoked DVT with one or
more risk factors.
At initial presentation, DVT was located in the iliofe-
moral segment in 22 patients (19%), the femoropopliteal
segment in 42 (36%), and the calf veins in 52 (45%). Pa-
tients were anticoagulated for a mean duration of 18
months. The most common triggering factor for DVT
was surgery (45 patients [39%]), followed by hormone
replacement therapy (16 patients [14%]) and active can-
cer (15 patients [13%]).
At the 6-month follow-up point, venous duplex ultra-
sound revealed no venous abnormalities in 46% of the
patients. On the other hand, 18% of the patients had
Fig 2. Study ﬂow diagram. In the cohort study, 129 consecutive patients were enrolled; ﬁve patients were
excluded and eight were lost to follow-up, leaving 116 patients who were eligible for the study. DVT, Deep
venous thrombosis; NIRS, near-infrared spectroscopy; PTS, post-thrombotic syndrome.
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Volume 4, Number 4venous obstruction, 14% had reﬂux, and the remaining
22% had both obstruction and reﬂux. No patients had
clinical evidence of PTS.
Presenting characteristics associated with PTS. Of the
116 patients evaluated, 19 (16%) ﬁnally developed PTS.
Table I summarizes and compares the characteristics of
the patients with and without PTS. In this cohort, there
were 16 patients with mild and 3 with moderate disease,
and no patients had severe disease. There were no sig-
niﬁcant differences in mean age and age category or
gender distribution between the two groups. Similarly,
there were no signiﬁcant intergroup differences in BMI or
BMI category. The duration of anticoagulation was 19
months in patients with PTS and 18 months in patients
without PTS, the intergroup difference being nonsigniﬁ-
cant. There were no signiﬁcant differences in risk factors
between patients with and without PTS. On the other
hand, patients who had idiopathic DVT had a higher
incidence of PTS (P < .01). With regard to the anatomic
distribution of DVT, the incidence of iliofemoral DVT was
signiﬁcantly higher in patients with PTS than in those
without (P < .01). On the other hand, femoropopliteal
DVT was evenly distributed between the two groups
(P ¼ .10). By contrast, patients with calf DVT were signif-
icantly less likely to develop PTS (P < .01).At 6 months, the proportion of patients with occlusion
alone did not differ between the groups. Similarly, there
was no signiﬁcant intergroup difference in the presence
of reﬂux alone. By contrast, the proportion of patients
with both reﬂux and obstruction was signiﬁcantly higher
in the PTS group (P < .01).
Table II compares the ﬁnal CEAP clinical manifestations
between patients with and without PTS. Among the 19
patients with PTS, 11 (58%) had severe edema (CEAP
C3) and 8 (42%) had CEAP C4. On the other hand, among
the 97 patients without PTS, 75 (77%) had no visible
venous disease (CEAP C0), 8 (8%) had telangiectasia or
reticular veins (CEAP C1), 4 (4%) had varicose veins
(CEAP C2), and 10 (11%) had edema. No recurrent DVTs
were encountered during the follow-up period of 6 years.
NIRS measurements. Table III compares the NIRS-
derived parameters in patients with and without PTS
measured at 6 months after DVT. Adoption of a standing
position caused increases in the level of both O2Hb and
HHb. While patients were standing, there was no signif-
icant difference in DO2Hbst between those with and
those without PTS (8 6 6 mmol/L, 11 6 10 mmol/L; P ¼ .44).
Similarly, there was no signiﬁcant difference in DHHbst
between patients with and those without PTS (11 6 10
mmol/L, 14 6 7 mmol/L; P ¼ .18). The values of HbDst in the
Table I. Comparison of characteristics between patients
with and without post-thrombotic syndrome (PTS)
PTS
(n ¼ 19)
No PTS
(n ¼ 97) P value
Characteristics at initial visit
Age, years 57.2 6 15.5 61.3 6 18.3 .27a
Age category
<40 years 3 (15.8) 12 (12.4) .69b
40-65 years 9 (47.4) 32 (33.0) .23b
$65 years 7 (36.8) 53 (54.6) .16b
Male gender 10 (52.6) 32 (33.0) .10b
BMI, kg m2 25.2 6 2.3 22.6 6 3.1 .34a
BMI category
<18.5 kg m2 1 (5.3) 3 (3.1) .52b
18.5-25 kg m2 10 (52.6) 62 (63.9) .36b
25-30 kg m2 8 (42.1) 28 (28.9) .26b
$30 kg m2 0 (0) 4 (4.1) .37b
Duration of oral
anticoagulation,
months
18.9 6 14.7 18.1 6 28.2 .90a
Risk factors
Active cancer 1 (5.3) 14 (14.4) .28b
Congestive heart failure 0 (0) 1 (1.0) .66b
Hormone
replacement therapy
4 (21.1) 12 (12.4) .32b
Immobilization 0 (0) 12 (12.4) .11b
Renal failure 2 (10.5) 5 (5.2) .37b
Surgery 5 (26.3) 40 (41.2) .22b
Stroke 2 (10.5) 2 (2.1) .06b
Idiopathic DVT 7 (36.8) 12 (12.4) <.01b
Distribution of DVT
Iliofemoral DVT 8 (42.1) 14 (14.4) <.01b
Femoropopliteal DVT 10 (52.6) 32 (33.0) .10b
Calf DVT 1 (5.3) 51 (52.6) <.01b
Venous abnormality at 6 months
No abnormalities 1 (5.2) 52 (53.6) <.01b
Obstruction 5 (26.3) 16 (16.5) .31b
Reﬂux 4 (21.1) 12 (12.4) .32b
Obstruction and reﬂux 9 (47.4) 17 (17.5) <.01b
BMI, Body mass index; DVT, deep venous thrombosis.
Categorical variables are presented as number (%). Continuous vari-
ables are presented as mean 6 standard deviation.
aStudent t-test.
bPearson c2 test or Fisher exact test.
Table II. Numbers of patients with each Clinical, Etiologic,
Anatomic, and Pathophysiologic (CEAP) clinical class at 60
months
Class Signs and symptoms
PTS
(n ¼ 19)
No PTS
(n ¼ 97)
C0 No visible or palpable signs of
venous disease
0 (0) 75 (77)
C1 Telangiectasia or reticular veins 0 (0) 8 (8)
C2 Varicose veins; distinguished from
reticular veins by a diameter of
3 mm or more
0 (0) 4 (4)
C3 Edema 11 (58) 10 (11)
C4 Pigmentation, eczema,
lipodermatosclerosis, or
atrophie blanche
8 (42) 0 (0)
C5 Healed venous ulcer 0 (0) 0 (0)
C6 Active venous ulcer 0 (0) 0 (0)
Values are expressed as No. (%).
Table III. Near-infrared spectroscopy (NIRS)-derived pa-
rameters compared between patients with and without
post-thrombotic syndrome (PTS)
PTS (n ¼ 19)
No PTS
(n ¼ 97) P valuea
On standing
DO2Hbst, mmol/L 8 6 6 11 6 10 .44
DHHbst, mmol/L 11 6 10 14 6 7 .18
HbDst, mmol/L 13 6 14 10 6 15 .61
TO2Hbst, seconds 38 6 33 63 6 35 .04
THHbst, seconds 190 6 73 210 6 59 .38
During exercise
DO2Hbex, mmol/L 15 6 10 11 6 7 .22
DHHbEex, mmol/L 3 6 4 6 6 3 .04
DHHbRex, mmol/L 8 6 9 6 6 3 .28
HbDex, mmol/L 6 6 25 5 6 14 .91
Values are expressed as mean 6 standard deviation.
aStudent t-test.
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October 2016two groups were also similar (13 6 14 mmol/L, 10 6 15
mmol/L; P ¼ .61). In contrast, the time taken for the in-
crease in O2Hb concentration to become maximal
(TO2Hbst) was signiﬁcantly shorter in patients with PTS
than in those without (38 6 33 seconds, 63 6 35 seconds;
P ¼ .04). There was no signiﬁcant difference in the value
of THHbst between patients with and those without PTS
(190 6 73 seconds, 210 6 59 seconds; P ¼ .38). In patients
who were not at risk for development of PTS, O2Hb and
HHb gradually increased simultaneously until plateaushad been reached. In contrast, patients who were at risk
for development of PTS had reduced TO2Hbst. The
TO2Hbst curve reached a plateau within a short time and
then began to decrease while HHb continued to
increase.
Ten tiptoe movements produced a continuous
decrease of calf muscle O2Hb in both groups, and there
was no signiﬁcant intergroup difference in DO2Hbex
(15 6 10 mmol/L, 11 6 7 mmol/L; P ¼ .22). On the other
hand, this maneuver resulted in venous expulsion
(DHHbEex) and subsequent retention (DHHbRex). The
DHHbEex value was signiﬁcantly decreased in patients
with PTS relative to those without PTS (3 6 4 mmol/L,
6 6 3 mmol/L; P ¼ .04). On the other hand, there was
no signiﬁcant difference in DHHbRex between the groups
(8 6 9 mmol/L, 6 6 3 mmol/L; P ¼ .28). Similarly, there were
Fig 3. Ability of near-infrared spectroscopy (NIRS)-derived confounding parameters to predict post-thrombotic
syndrome (PTS). A, NIRS-derived TO2Hbst #48 seconds had the highest area under the curve (0.88; 95% con-
ﬁdence interval [CI], 0.80-0.93; P < .01) with a sensitivity of 90% and a speciﬁcity of 83%. B, When a DHHbEex
cutoff point of 0.87 mmol/L was used, the clinical discrimination performance was not signiﬁcant with a
sensitivity of 32% and a speciﬁcity of 80% (area under the curve, 0.53; 95% CI, 0.43-0.62; P ¼ .73).
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(6 6 25 mmol/L, 5 6 14 mmol/L; P ¼ .91).
Ability of NIRS-derived confounding parameters to
predict PTS. Using NIRS-derived TO2Hbst and DHHbEex
as possible discriminative confounding variables, a
separate receiver operating characteristic curve analysis
was conducted to identify the most suitable cutoff
points with the highest accuracy and minimal false
negativity and false positivity for discrimination between
the PTS and non-PTS groups (Fig 3). Of these, NIRS-
derived TO2Hbst #48 seconds had the highest area
under the curve (0.88; 95% conﬁdence interval [CI], 0.80-
0.93; P < .01) with a sensitivity of 90% and a speciﬁcity of
83%. In contrast, when a DHHbEex cutoff point of 0.87
mmol/L was used, the clinical discrimination perfor-
mance was not signiﬁcant, with a sensitivity of 32% and a
speciﬁcity of 80% (area under the curve, 0.53; 95% CI,
0.43-0.62; P ¼ .73).
Predictors of PTS. Univariate analysis revealed that vari-
ables associated with greater risk for development of PTS
(P < .10) were stroke (odds ratio [OR], 5.59; 95% CI, 0.74-
42.41; P ¼ .06), idiopathic DVT (OR, 4.13; 95% CI, 1.36-12.55;
P < .01) and iliofemoral DVT (OR, 4.31; 95% CI, 1.48-12.60;
P < .01) at initial presentation, venous occlusion combined
with reﬂux (OR, 4.24; 95% CI, 1.50-12.00; P < .01), and NIRS-
derived TO2Hbst #48 seconds (OR, 43.03; 95% CI, 9.04-
204.81; P < .01) at 6 months (Table IV).
The confounding predictors of PTS were then ﬁnally
tested using multivariate logistic regression analysis(Table V). Although univariate analysis had suggested
that thrombus involvement of the iliofemoral venous
segment at initial presentation was a predictor of PTS,
this factor was not found to be signiﬁcantly associated
with the development of PTS. Similarly, stroke and idio-
pathic DVT were shown not to be predictors of PTS. At
the 6-month point, venous occlusion combined with
reﬂux was predictive of PTS (OR, 4.80; 95% CI, 1.03-22.36;
P < .05). Furthermore, TO2Hbst #48 seconds detected by
NIRS was the strongest predictor of PTS at the 6-month
follow-up point (OR, 53.73; 95% CI, 8.43-342.41; P < .01).
DISCUSSION
Since the introduction of NIRS in 1977 by Jöbsis as a
valid and noninvasive method for measurement of tissue
oxygenation,14 numerous studies have developed and
reﬁned the NIRS approach for investigating skeletal mus-
cle hemodynamics and metabolism in vivo.15-19 In a pre-
vious study to investigate the correlation of clinical
severity with NIRS-derived HHb in patients with chronic
venous diseases, we found that the ﬁlling index (FI-HHb),
calculated by dividing 90% of the HHb by the time taken
to ﬁll 90% of the HHb on standing, and the retention
index (RI-HHb), determined as HHbR/HHbE during exer-
cise measured by NIRS, were increased in patients with
advanced chronic venous diseases.20 Moreover, RI-HHb
>2.9 measured at 6 months after DVT was shown to
have a strong capability for predicting advanced symp-
toms of PTS.10 These results appear to reﬂect the possibil-
ity that increased calf muscle deoxygenation during
Table IV. Univariate analysis to evaluate potential pre-
dictors of post-thrombotic syndrome (PTS)
Variable OR 95% CI P value
Variables at initial visit
Age
<40 years 1.33 0.34-5.24 .69
40-65 years 1.83 0.68-4.95 .23
$65 years 4.13 1.36-12.6 .16
Male sex 2.26 0.83-6.11 .10
BMI
<18.5 kg m2 1.74 0.17-17.69 .64
18.5-25 kg m2 0.63 0.23-1.69 .36
25-30 kg m2 1.80 0.65-4.93 .25
$30 kg m2 0.96 0.92-1.00 .36
Risk factors for DVT
Active cancer 0.33 0.41-2.67 .28
Congestive heart failure 0.99 0.97-1.01 .66
Hormone replacement
therapy
1.89 0.54-6.64 .32
Immobilization 0.88 0.81-0.94 .11
Renal failure 2.16 0.39-12.08 .37
Surgery 0.51 0.17-1.53 .22
Stroke 5.59 0.74-42.41 .06
Idiopathic DVT 4.13 1.36-12.55 <.01
Distribution of DVT
Iliofemoral DVT 4.31 1.48-12.60 <.01
Femoropopliteal DVT 2.26 0.83-6.11 .10
Calf DVT 0.05 0.01-0.39 <.01
Variables at 6 months
Venous abnormalities
No abnormality 0.05 0.01-0.38 <.01
Obstruction alone 1.81 0.57-5.73 .31
Reﬂux alone 1.89 0.54-6.64 .32
Obstruction and reﬂux 4.24 1.50-12.00 <.01
NIRS-derived parameters
TO2Hbst #48 seconds 43.03 9.04-204.81 <.01
DHHbEex, mmol/L 2.52 0.83-7.68 .10
BMI, Body mass index; CI, conﬁdence interval; DVT, deep venous
thrombosis; OR, odds ratio.
Table V. Multivariate logistic regression analysis to eval-
uate ﬁnal predictors of post-thrombotic syndrome (PTS)
Variable b Wald OR 95% CI P value
Stroke 1.00 0.31 2.73 0.08-92.63 .58
Idiopathic DVT 0.02 0.01 0.98 0.16-5.99 .98
Iliofemoral DVT 1.40 2.45 4.07 0.02-23.63 .12
Obstruction and
reﬂux
1.57 4.00 4.81 10.3-22.36 <.05
TO2Hbst #48 seconds 3.98 17.78 53.73 8.43-342.41 <.01
CI, Conﬁdence interval; DVT, deep venous thrombosis; OR, odds ratio.
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tients with a ﬁrst episode of DVT.
Another relevant issue related to chronic venous dis-
ease is the role of arterial perfusion in relation to clinical
symptoms. Several investigators have applied various
plethysmographic methods for detection of arterial
perfusion and found increased resting arterial perfusion
and reduced arterial inﬂow during the hyperemic
response in patients with severe chronic venous disor-
ders.21-23 These ﬁndings lend support to the view that
chronic venous insufﬁciency is a condition that affects
both the venous and arterial systems of the lower ex-
tremities at the microcirculation level. The disadvantagesof plethysmographic examination include the use of
different systems for assessment of venous and arterial
inﬂows. Accordingly, little is known about the venous
and arterial inter-relationship in patients with chronic
venous diseases revealed by various forms of plethys-
mography. In contrast, NIRS can examine calf muscle
O2Hb and HHb simultaneously in every patient with
DVT without the use of occlusion cuffs while the patients
are standing and doing exercise, thus better reﬂecting
natural activities during daily life.
In our previous study comparing patients with and
without conﬁrmed PTS, we found that in PTS patients,
TO2Hbst was signiﬁcantly decreased on standing and
that during exercise, DHHbEex was signiﬁcantly
decreased whereas DHHbRex was signiﬁcantly increased.
Similarly, the falls in HbDex were more pronounced in
PTS patients.6 In the present study, TO2Hbst #48 seconds
was the only NIRS-derived predictor of PTS at the 6-
month follow-up point. Therefore, it appeared that
NIRS-derived O2Hb was able to reveal the earliest
change in PTS rather than the change in HHb during
follow-up of patients with DVT.
The mechanisms underlying the changes in O2Hb dur-
ing the development of advanced symptoms of PTS still
remain unclear. As we assumed in our previous studies,6,9
the fact that TO2Hbst is reduced in patients with
advanced symptoms of chronic venous disease may indi-
cate impairment of the venoarteriolar reﬂex. Long-
standing venous hypertension ultimately causes changes
in the microcirculation23 and may result in reﬂex arteri-
olar vasoconstriction in response to venous hypertension.
Patients who have venous obstruction and reﬂux at 6
months after DVT are expected to have chronic exposure
to venous hypertension, unlike those without venous ab-
normalities. In our previous study, we found that patients
with conﬁrmed PTS had signiﬁcantly decreased
DHHbEex and increased DHHbRex relative to those
without PTS. This ﬁnding reﬂects the fact that patients
with conﬁrmed PTS have more severe impairment of
the calf muscle pump than those without.6 However, in
the present study, we did not ﬁnd any predictive value
of changes in both DHHbEex and DHHbRex at 6 months,
suggesting that impairment of the calf muscle pump
may develop in the later phase. In this background, we
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ment of PTS as well as candidates for intervention that
would decrease the risk for development of PTS at 6
months. At this point, patients who were found to be at
risk for PTS were encouraged to wear compression stock-
ings for more than 6 months. In contrast, patients who
were found to have no risk for development of PTS at
the 6-month follow-up point were ready to stop wearing
compression stockings. Furthermore, patients with a
high risk of PTS were potential candidates for subse-
quent neovalve construction.24
There were some limitations to the interpretation of our
NIRS ﬁndings. We did not ﬁnd any signiﬁcant relation-
ships between baseline characteristics and risk factors
for PTS. This was mainly due to our relatively small sam-
ple size and the high interindividual variability of the
data. Only changes in TO2Hbst suggest that the observed
effect is independent of small sample size and reﬂects a
physiologically relevant phenomenon. Therefore, to
conﬁrm the relationship between the investigated pa-
rameters and the clinical prediction of PTS, a large sam-
ple size will be required. Furthermore, in this cohort, we
did not ﬁnd any patients with advanced symptoms of
PTS (Villalta sore $15, presence of venous ulcer, or CEAP
clinical class C5 or C6) at 6 years. Nevertheless, we believe
that our ﬁndings may have important implications for in-
vestigations of the microcirculation in the context of
post-thrombotic sequelae.
CONCLUSIONS
We have found that in patients with DVT, venous occlu-
sion combined with reﬂux was predictive of PTS at the 6-
month point. Furthermore, TO2Hbst #48 seconds was the
only strong NIRS-derived predictor of PTS. These ﬁndings
suggest that chronic exposure to venous hypertension
resulting from venous obstruction and reﬂux could affect
calf muscle oxygenation at a relatively early stage of DVT.
Further studies using a multicentered approach will be
needed to conﬁrm the usefulness of NIRS for evaluation
of disease severity.
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